Manuscripts and Publications

Filters: Keyword is Pre-Exposure Prophylaxis  [Clear All Filters]
2021
Biello KB, Hill-Rorie J, Valente PK, Futterman D, Sullivan PS, Hightow-Weidman L, Muessig K, Dormitzer J, Mimiaga MJ, Mayer KH.  2021.  Development and Evaluation of a Mobile App Designed to Increase HIV Testing and Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: Open Pilot Trial.. J Med Internet Res. 23(3):e25107.
Piper KN, Escoffery C, Sales JM, Sheth AN.  2021.  Models of HIV Pre-Exposure Prophylaxis Care Used in Title X Family Planning Clinics in the Southern U.S.. J Adolesc Health. 68(3):480-487.
Siegler AJ.  2021.  Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use.. Clin Infect Dis. 72(3):386-387.
Sales JM, Escoffery C, Hussen SA, Haddad LB, McCumber M, Kwiatkowski E, Filipowicz T, Sanchez M, Psioda MA, Sheth AN.  2021.  Pre-exposure Prophylaxis Implementation in Family Planning Services Across the Southern United States: Findings from a Survey Among Staff, Providers and Administrators Working in Title X-Funded Clinics.. AIDS Behav. 25(6):1901-1912.
Robles G, Sauermilch D, Gandhi M, Starks TJ.  2021.  PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men. AIDS Behav. 25(4):1299-1305.
A Rosengren L, Lelutiu-Weinberger C, E Woodhouse W, Sandanapitchai P, Hightow-Weidman LB.  2021.  A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men.. AIDS Behav. 25(7):2054-2070.
Saleska JLonderee, Lee S-J, Leibowitz A, Ocasio M, Swendeman D.  2021.  A Tale of Two Cities: Exploring the Role of Race/Ethnicity and Geographic Setting on PrEP Use Among Adolescent Cisgender MSM.. AIDS Behav. 25(1):139-147.
2020
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Sullivan PS, Mouhanna F, Mera R, Pembleton E, Castel AD, Jaggi C, Jones J, Kramer MR, McGuinness P, McCallister S et al..  2020.  Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.. Ann Epidemiol. 44:16-30.
Saleska JLonderee, Lee S-J.  2020.  Normalization of Preexposure Prophylaxis for Adolescents. JAMA Pediatr. 174(12):1133-1134.
Siegler AJ, C Mehta C, Mouhanna F, Giler RMera, Castel A, Pembleton E, Jaggi C, Jones J, Kramer MR, McGuinness P et al..  2020.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.. Ann Epidemiol. 45:24-31.e3.
Siegler AJ.  2020.  Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision.. Am J Public Health. 110(3):267-268.
Siegler AJ, Wiatrek S, Mouhanna F, K Amico R, Dominguez K, Jones J, Patel RR, Mena LA, Mayer KH.  2020.  Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions.. AIDS Behav. 24(9):2637-2649.
2017
Reisner SL, Jadwin-Cakmak L, Hughto JMWhite, Martinez M, Salomon L, Harper GW.  2017.  Characterizing the HIV Prevention and Care Continua in a Sample of Transgender Youth in the U.S.. AIDS Behav. 21(12):3312-3327.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Mullins TLKowalczy, Zimet G, Lally M, Xu J, Thornton S, Kahn JA.  2017.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.